Aricept
Developed to mitigate cognitive decline to support memory retention and alleviate daily behavioural changes.
Aricept details
- Conditions
- Alzheimer's Disease · Dementia
- Alternative names
- donepezil
- Therapeutic class
- Acetylcholinesterase Inhibitor
- Pharmacological class
- Cholinesterase Inhibitor
- Known off-label uses
- vascular dementia
- Contraindications
- hypersensitivity to donepezil; hypersensitivity to piperidine derivatives
- Minor side effects
- diarrhoea; nausea; insomnia
- Moderate side effects
- muscle cramps; fatigue; anorexia
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Originator
- Eisai
- Onset Time
- 2–4 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- NSAIDs; Ketoconazole; Quinidine
- Age restrictions
- Approved for adults.
Serious side effects
severe bradycardia, requires immediate medical attention; gastrointestinal haemorrhage, requires immediate medical attention
Patient summary
developed to mitigate cognitive decline to support memory retention and alleviate daily behavioural changes.
Mechanism of action
Inhibits acetylcholinesterase, leading to increased levels of acetylcholine available in synapses within the central nervous system.
Pregnancy and breastfeeding
TGA Category C: Use if potential benefit outweighs risk. Breastfeeding: Consult a doctor.
What you will receive
Aricept is the originator brand name, made by Eisai. We use it to identify the medicine and are not affiliated with Eisai.
- The fulfilment partner confirms whether the exact brand or an equivalent containing Donepezil is offered.
- The offered brand, manufacturer and dispatch location depend on the product, destination and partner warehouse.
- Check the final product details at checkout before confirming an order.